Matairesinol
Based on 1 Customer Validation
Matairesinol is an orally active bioactive compound with anti-inflammatory, antioxidant and anticancer activities. Matairesinol inhibits the phosphorylation of MAPK, JNK and NF-κB, downregulates RANKL-induced NFATc1 expression and activity, and suppresses the activation of the PI3K/AKT/FOXO1 pathway. Matairesinol can be used in research related to sepsis-mediated brain injury, osteoporosis, heart failure, atopic dermatitis and cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.78%
- CAS. Nr.: 580-72-3
- Formel: C20H22O6
- Molecular Weight:358.39
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
23.8 μM
Compound: 10
|
Anticancer activity against human A549 cells by SRB assay
Anticancer activity against human A549 cells by SRB assay
|
[PMID: 21420296] |
| BV-2 | IC50 |
94.53 μM
Compound: 10
|
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of lipopolysaccharide induced NO production
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of lipopolysaccharide induced NO production
|
[PMID: 21420296] |
| H9 | EC50 |
2 μM
Compound: 1
|
Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication
Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication
|
[PMID: 11473435] |
| H9 | IC50 |
21.9 μM
Compound: 1
|
Cytotoxicity against human H9 cells
Cytotoxicity against human H9 cells
|
[PMID: 11473435] |
| HeLa | EC50 |
>100 μM
Compound: 2
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by WST-8 assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by WST-8 assay
|
[PMID: 28754364] |
| HeLa | CC50 |
>50 μM
Compound: 9
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by SRB assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by SRB assay
|
[PMID: 30676026] |
| HepG2 | IC50 |
15.1 μg/mL
Compound: 8
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay
|
[PMID: 32223924] |
| HL-60 | EC50 |
74 μM
Compound: 2
|
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by WST-8 assay
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by WST-8 assay
|
[PMID: 28754364] |
| Neutrophil | IC50 |
4.3 μg/mL
Compound: 19
|
Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins
Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins
|
[PMID: 28218000] |
| Neutrophil | IC50 |
7.3 μg/mL
Compound: 19
|
Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate
Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate
|
[PMID: 28218000] |
| Neutrophil | IC50 |
2.7 μM
Compound: 8
|
Anti-inflammatory activity against human neutrophils assessed as inhibition of fMLF/CB-induced superoxide anion generation preincubated for 5 mins followed by fMLF addition after priming with CB for 3 mins and measured after 10 mins by spectrophotometric
Anti-inflammatory activity against human neutrophils assessed as inhibition of fMLF/CB-induced superoxide anion generation preincubated for 5 mins followed by fMLF addition after priming with CB for 3 mins and measured after 10 mins by spectrophotometric
|
[PMID: 32223924] |
| Neutrophil | IC50 |
6.6 μM
Compound: 8
|
Anti-inflammatory activity against human neutrophils assessed as inhibition of fMLF/CB-induced elastase release preincubated for 5 mins followed by fMLF addition after priming with CB for 3 mins and measured after 10 mins by spectrophotometric analysis
Anti-inflammatory activity against human neutrophils assessed as inhibition of fMLF/CB-induced elastase release preincubated for 5 mins followed by fMLF addition after priming with CB for 3 mins and measured after 10 mins by spectrophotometric analysis
|
[PMID: 32223924] |
| RAW264.7 | IC50 |
0.005 mM
Compound: 9
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs
|
[PMID: 18986199] |
| RAW264.7 | IC50 |
0.005 μM/mL
Compound: 9
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs
|
[PMID: 18986199] |
| SK-MEL-2 | IC50 |
>30 μM
Compound: 10
|
Anticancer activity against human SK-MEL-2 cells by SRB assay
Anticancer activity against human SK-MEL-2 cells by SRB assay
|
[PMID: 21420296] |
| SK-OV-3 | IC50 |
>30 μM
Compound: 10
|
Anticancer activity against human SKOV3 cells by SRB assay
Anticancer activity against human SKOV3 cells by SRB assay
|
[PMID: 21420296] |
| XF498 | IC50 |
23.65 μM
Compound: 10
|
Anticancer activity against human XF498 cells by SRB assay
Anticancer activity against human XF498 cells by SRB assay
|
[PMID: 21420296] |
In Vitro
Matairesinol (1-80 μM; 48 h) exhibits minimal toxicity to NSC-34 and HT22 neuronal cells at concentrations up to 40 μM, with significant cytotoxicity only at 80 μM after 48 h of treatment[1].
Matairesinol (5-20 μM; 48 h) reverses the anti-proliferative and pro-apoptotic effects of LPS on NSC-34 and HT22 neuronal cells, with effects detectable at 24, 48, and 72 h post-treatment[1].
Matairesinol (5-20 μM; 48 h) attenuates LPS-mediated oxidative stress and inflammation in BV2 microglia, while modulating the expression of Nrf2/HO-1 and inhibiting MAPK/JNK/NF-κB pathway activation[1].
Matairesinol (0.3-30 μM; 4 days) dose-dependently inhibits RANKL-induced differentiation of mouse bone marrow-derived macrophages into osteoclasts, with significant inhibition observed at concentrations ≥10 μM for osteoclast formation and ≥1 μM for TRAP activity[2].
Matairesinol (0.3-30 μM; 3 days) does not reduce the viability of mouse bone marrow-derived macrophages[2].
Matairesinol (10 μM; 1-3 days) suppresses RANKL-induced expression of NFATc1 and downstream osteoclastogenesis-associated genes (TRAP, OSCAR, v-ATPasev0d2) in mouse bone marrow-derived macrophages over 1-3 days of treatment[2].
Matairesinol (10 μM; 4 days, following 8 h retroviral infection) has its inhibitory effect on RANKL-induced osteoclast differentiation reversed by ectopic overexpression of constitutively active NFATc1 in mouse bone marrow-derived macrophages, confirming NFATc1 as a key mediator of its anti-osteoclastogenic activity[2].
Matairesinol (10 μM; 1 h pre-incubation, followed by RANKL stimulation for 5, 15, 30 min) suppresses RANKL-induced activation of p38 and ERK (but not JNK) MAPK signaling pathways in mouse bone marrow-derived macrophages[2].
Matairesinol (0-100 μM) at 50 μM maintains viability in Ang II-stimulated NRVMs, while 100 μM reduces viability under basal conditions[3].
Matairesinol (50 μM) attenuates Ang II-induced hypertrophy in NRVMs by reducing cell size and suppressing hypertrophy-related gene expression[3].
Matairesinol (50 μM) inhibits Ang II-induced activation of NRCFs by reducing fibrotic marker expression and suppressing the TGF-β/Smad3 pathway[3].
Matairesinol (50 μM) ameliorates oxidative stress in Ang II-stimulated NRVMs by reducing ROS levels[3].
Matairesinol (10-500 μM; 72 h) inhibits proliferation of HUVECs (IC50 75 μM) more potently than HeLa cells (IC50 200 μM)[5].
Matairesinol (10-100 μM; 48 h, 72 h) does not induce cytotoxicity in HUVECs at concentrations up to 50 μM when treated for 72 h, or at 100 μM when treated for 48 h[5].
Matairesinol (10-20 μM; 3-16 h) dose-dependently inhibits VEGF-induced capillary tube formation in serum-starved HUVECs[5].
Matairesinol (20-80 μM) dose-dependently reduces PCNA protein expression in PANC-1 and MIA PaCa-2 pancreatic cancer cells, with 80 μM causing a 30% and 33% reduction in the respective cell lines[6].
Matairesinol (80 μM; 3 days) inhibits 3D spheroid formation in PANC-1 and MIA PaCa-2 pancreatic cancer cells, reducing spheroid area by 78% and 61% in the respective cell lines[6].
Matairesinol (20-80 μM; 48 h) dose-dependently induces late apoptosis in PANC-1 and MIA PaCa-2 pancreatic cancer cells, with 80 μM increasing late apoptosis by 196% and 261% in the respective cell lines over 48 h[6].
Matairesinol (20-80 μM; 1 h) dose-dependently increases intracellular ROS production in PANC-1 and MIA PaCa-2 pancreatic cancer cells, with 80 μM increasing ROS by 447% and 548% in the respective cell lines after 1 h[6].
Matairesinol (20-80 μM; 48 h) dose-dependently increases cytosolic calcium levels in PANC-1 and MIA PaCa-2 pancreatic cancer cells, with 80 μM increasing levels by 280% and 551% in the respective cell lines over 48 h[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:NSC-34, HT22
-
Concentration:1, 2, 40, 80 μM
-
Incubation Time:48 h
-
Result:Showed no significant cytotoxicity at 1, 2, and 40 μM compared to the control group.
Significantly hindered cell viability at 80 μM compared to the control group.
-
Cell Line:human umbilical vein endothelial cells (HUVECs), HeLa cells
-
Concentration:10-500 μM
-
Incubation Time:72 h
-
Result:Inhibited HUVEC proliferation with an IC50 of 75 μM.
Inhibited HeLa cell proliferation with an IC50 of 200 μM.
-
Cell Line:HUVECs (VEGF-stimulated, serum-starved)
-
Concentration:10-20 μM
-
Incubation Time:18 h
-
Result:Dose-dependently inhibited VEGF-induced HUVEC invasiveness without cytotoxic effects.
-
Cell Line:PANC-1, MIA PaCa-2 human pancreatic ductal adenocarcinoma cells
-
Concentration:5-100 μM; 80 μM (optimal dose)
-
Incubation Time:48 h
-
Result:Inhibited cell proliferation by 48% in PANC-1 cells and 50% in MIA PaCa-2 cells (p < 0.001 for both cell lines).
-
Cell Line:PANC-1, MIA PaCa-2 cells
-
Concentration:20-80 μM
-
Incubation Time:48 h
-
Result:Increased relative late apoptosis by 196% in PANC-1 cells and 261% in MIA PaCa-2 cells, with late apoptosis increasing in a dose-dependent manner.
-
Cell Line:PANC-1, MIA PaCa-2 cells
-
Concentration:80 μM
-
Incubation Time:24 h
-
Result:Reduced the number of migrated cells by 79% in PANC-1 cells and 86% in MIA PaCa-2 cells.
-
Cell Line:PANC-1, MIA PaCa-2 cells
-
Concentration:80 μM (in combination with 20 μM 5-FU)
-
Incubation Time:48 h
-
Result:Reduced cell proliferation from 73% to 34% in PANC-1 cells and from 74% to 30% in MIA PaCa-2 cells compared to 5-FU alone.
-
Cell Line:MIA PaCa-2 cells
-
Concentration:80 μM (in combination with 20 μM 5-FU)
-
Incubation Time:48 h
-
Result:Increased relative late apoptosis from 473% to 704% in MIA PaCa-2 cells compared to 5-FU alone.
In Vivo
Matairesinol (100 mg·kg−1·d−1; intraperitoneal injection; daily; 3 weeks) improves cardiac function, reduces cardiac hypertrophy and remodeling, inhibits cardiomyocyte apoptosis, and mitigates oxidative stress in TAC-induced mice by upregulating Prdx1 and inhibiting the PI3K/AKT/FOXO1 pathway, with these effects blunted by Prdx1 knockdown[3].
Matairesinol (topical; daily; 11 days) effectively suppresses DfE-induced atopic dermatitis in NC/Nga mice by reducing ear swelling, serum IgE levels, inflammatory cell infiltration, mast cell numbers, and normalizing IL-4 and IFN-γ mRNA expression[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:unspecified (6-8 weeks old)[1]
-
Dosage:5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced serum concentrations of S100β, GFAP, and NSE relative to CLP-only rats, with significant effects at 10 and 20 mg/kg for all three markers.
Reduced brain tissue expression of Caspase-3 relative to CLP-only rats, with significant effects at 10 and 20 mg/kg.
Reduced serum and brain tissue levels of pro-inflammatory cytokines TNF-α, IL-1β, IL-6, IFN-γ, IL-8, and MCP1 relative to CLP-only rats, with significant effects at 10 and 20 mg/kg for all cytokines.
Reduced the number of Iba-1-positive activated microglia in brain tissue relative to CLP-only rats, with significant effects at 10 and 20 mg/kg.
-
Animal Model:C57BL/6 (male, 8-10 weeks old, 23-28 g, transverse aortic constriction surgery-induced)[3]
-
Dosage:100 mg·kg-1·d-1
-
Administration:intraperitoneal injection; daily; 3 weeks
-
Result:Restored left ventricular ejection fraction (EF) and fractional shortening (FS), and reduced left ventricular end-diastolic dimension (LVEDd) in TAC-induced mice.
Reduced heart weight-to-body weight ratio (HW/BW) and heart weight-to-tibia length ratio (HW/TL).
Suppressed mRNA expression of hypertrophy markers ANP, BNP, and β-MHC.
Normalized protein expression of apoptosis-related markers (reduced Bax and Caspase3, increased Bcl-2).
Reduced myocardial reactive oxygen species (ROS) levels.
Restored protein expression of antioxidant markers HO-1 and SOD2.
Chemical Information
-
CAS. Nr. 580-72-3
-
Appearance Solid
-
Molecular Weight 358.39
-
Formel C20H22O6
-
Color White to yellow
-
SMILES
O=C1OC[C@H](CC2=CC=C(O)C(OC)=C2)[C@H]1CC3=CC=C(O)C(OC)=C3
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 200 mg/mL (558.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
TPA/Croton Oil Ear Edema and Dermatitis
The TPA (12-O-tetradecanoylphorbol-13-acetate) and croton oil-induced mouse ear edema model is a well-established acute cutaneous inflammation system used to evaluate topical anti-inflammatory activity by measuring edema formation, neutrophil infiltration, vascular permeability, and cytokine-mediated skin responses in vivo. The inflammatory response is triggered by topical application of phorbol esters (TPA) or croton oil constituents, leading to rapid activation of protein kinase C signaling, leukocyte recruitment, and increased vascular permeability, which can be quantified by ear thickness, weight, dye extravasation, and biochemical markers such as myeloperoxidase (MPO) activity and pro-inflammatory mediators in ear tissue homogenates. This model is widely used for screening anti-inflammatory agents, where reductions in edema and inflammatory biomarkers reflect suppression of acute dermal inflammation and immune cell infiltration. Histological evaluation typically confirms epidermal
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Reinheit & Dokumentation
-
Data Sheet (297 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Wu Q, et al. Matairesinol exerts anti-inflammatory and antioxidant effects in sepsis-mediated brain injury by repressing the MAPK and NF-κB pathways through up-regulating AMPK. Aging (Albany NY). 2021;13(20):23780-23795. [Content Brief]
[2]. Choi SW, et al. Anti-osteoclastogenic activity of matairesinol via suppression of p38/ERK-NFATc1 signaling axis. BMC Complement Altern Med. 2014;14:35. Published 2014 Jan 21. [Content Brief]
[3]. Zhang T, et al. Matairesinol blunts adverse cardiac remodeling and heart failure induced by pressure overload by regulating Prdx1 and PI3K/AKT/FOXO1 signaling. Phytomedicine. 2024;135:156054. [Content Brief]
[4]. Sung YY, et al. Forsythia suspensa fruit extracts and the constituent matairesinol confer anti-allergic effects in an allergic dermatitis mouse model. J Ethnopharmacol. 2016;187:49-56. [Content Brief]
[5]. Lee B, et al. Matairesinol inhibits angiogenesis via suppression of mitochondrial reactive oxygen species. Biochem Biophys Res Commun. 2012;421(1):76-80. [Content Brief]
[6]. Lee W, et al. Matairesinol Induces Mitochondrial Dysfunction and Exerts Synergistic Anticancer Effects with 5-Fluorouracil in Pancreatic Cancer Cells. Mar Drugs. 2022;20(8):473. Published 2022 Jul 25. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7903 mL | 13.9513 mL | 27.9026 mL | 69.7564 mL |
| 5 mM | 0.5581 mL | 2.7903 mL | 5.5805 mL | 13.9513 mL | |
| 10 mM | 0.2790 mL | 1.3951 mL | 2.7903 mL | 6.9756 mL | |
| 15 mM | 0.1860 mL | 0.9301 mL | 1.8602 mL | 4.6504 mL | |
| 20 mM | 0.1395 mL | 0.6976 mL | 1.3951 mL | 3.4878 mL | |
| 25 mM | 0.1116 mL | 0.5581 mL | 1.1161 mL | 2.7903 mL | |
| 30 mM | 0.0930 mL | 0.4650 mL | 0.9301 mL | 2.3252 mL | |
| 40 mM | 0.0698 mL | 0.3488 mL | 0.6976 mL | 1.7439 mL | |
| 50 mM | 0.0558 mL | 0.2790 mL | 0.5581 mL | 1.3951 mL | |
| 60 mM | 0.0465 mL | 0.2325 mL | 0.4650 mL | 1.1626 mL | |
| 80 mM | 0.0349 mL | 0.1744 mL | 0.3488 mL | 0.8720 mL | |
| 100 mM | 0.0279 mL | 0.1395 mL | 0.2790 mL | 0.6976 mL |